Complicated Urinary Tract Infection Treatment Market Report 2026

Complicated Urinary Tract Infection Treatment Market Overview

• Complicated Urinary Tract Infection Treatment market size has reached to $9.44 billion in 2025 • Expected to grow to $12.74 billion in 2030 at a compound annual growth rate (CAGR) of 6.1% • Growth Driver: Rising Incidence Of Chronic Kidney Disease To Drive Growth In The Market • Market Trend: Breaking Barriers In Infectious Disease Treatment With Anti-Infective Therapies • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Complicated Urinary Tract Infection Treatment Market?

Complicated urinary tract infection treatment refers to the medical management of a urinary tract infection (UTI) that occurs in individuals with underlying conditions that increase the risk of treatment failure. Complicated urinary tract infection treatment involves the use of targeted antibiotics and supportive therapies to address infections caused by resistant pathogens or underlying conditions that complicate recovery. It is used to manage severe urinary tract infection in patients with structural abnormalities, immunocompromised conditions, or catheter use, ensuring effective infection control and preventing complications. The main drug types of complicated urinary tract infection treatment are penicillin and combinations, quinolones, cephalosporins, azoles and amphotericin B, and nitrofurans. Penicillin and combinations refer to antibiotics derived from penicillin, often combined with beta-lactamase inhibitors to enhance effectiveness against resistant bacteria. These treatments are distributed through various channels, including hospital pharmacies, gynecology and urology clinics, and drug stores. They are used for various applications such as urethritis, cystitis, and pyelonephritis.

What Is The Complicated Urinary Tract Infection Treatment Market Growth Forecast?

The complicated urinary tract infection treatment market size is expected to see strong growth in the next few years. It will grow to $12.74 billion in 2030 at a compound annual growth rate (CAGR) of 6.1%. The growth in the forecast period can be attributed to development of novel antibiotics, growth in immunocompromised patient base, increasing use of outpatient infusion therapies, rising healthcare expenditure, improved pathogen identification technologies. Major trends in the forecast period include empiric therapy optimization, rising use of broad spectrum antibiotics, increased hospitalization for complicated UTIs, growing preference for combination drug therapies, expansion of hospital pharmacy based dispensing.

Global Complicated Urinary Tract Infection Treatment Market Segmentation

1) By Drug Class: Penicillin And Combinations, Quinolones, Cephalosporin, Azoles And Amphotericin B, Nitro Furans 2) By Distribution Channel: Hospital Pharmacies, Gynecology And Urology Clinics, Drug Stores 3) By Application: Urethritis, Cystitis, Pyelonephritis Subsegments: 1) By Penicillin And Combinations: Aminopenicillins, Beta-Lactamase Inhibitor Combinations 2) By Quinolones: Fluoroquinolones, Non-Fluoroquinolones 3) By Cephalosporin: First-Generation Cephalosporins, Second-Generation Cephalosporins, Third-Generation Cephalosporins, Fourth-Generation Cephalosporins, Fifth-Generation Cephalosporins 4) By Azoles And Amphotericin B: Triazoles, Imidazoles, Polyene Antifungals 5) By Nitrofurans: Nitrofurantoin, Furazolidone

What Is The Driver Of The Complicated Urinary Tract Infection Treatment Market?

Rising incidence of chronic kidney diseases is expected to propel the growth of the complicated urinary tract infection treatment market going forward. Chronic kidney disease (CKD) is a long-term condition characterized by the gradual loss of kidney function over time. The rising incidence of chronic kidney disease (CKD) is primarily due to increasing rates of diabetes and hypertension, along with aging populations and lifestyle factors such as obesity and smoking. Complicated urinary tract infection treatment supports chronic kidney disease (CKD) patients by preventing severe infections, such as pyelonephritis, that can exacerbate kidney damage, worsen renal function, and accelerate the progression of chronic kidney disease, ultimately reducing the risk of further complications and hospitalizations. For instance, in June 2024, according to the Australian Institute of Health and Welfare, an Australia-based government agency, in 2023, chronic kidney disease contributed 1.1% to the overall disease burden in Australia. Therefore, the rising incidence of chronic kidney diseases drives the complicated urinary tract infection treatment industry.

Key Players In The Global Complicated Urinary Tract Infection Treatment Market

Major companies operating in the complicated urinary tract infection treatment market are Pfizer Inc., Merck & Co. Inc., AbbVie Inc., AstraZeneca PLC, Fresenius Kabi AG, GlaxoSmithKline plc, bioMérieux SA, Shionogi & Co. Ltd., Cipla Limited, Santen Pharmaceutical Co. Ltd., Orchid Pharma Limited, Melinta Therapeutics Inc., Spero Therapeutics Inc., Nabriva Therapeutics AG, Venatorx Pharmaceuticals Inc., Recce Pharmaceuticals Ltd, MerLion Pharmaceuticals Pte. Ltd., Entasis Therapeutics Holdings Inc., Allecra Therapeutics GmbH, Allergan Inc.

Global Complicated Urinary Tract Infection Treatment Market Trends and Insights

Major companies operating in the complicated urinary tract infection treatment market are focusing on combating antibiotic resistance through novel antibiotics to enhance treatment efficacy and address emerging multidrug-resistant pathogens. Anti-infective therapies for complicated urinary tract infection treatment involve the use of targeted antibiotics or antimicrobial agents to eliminate or control infections, particularly in severe cases, where kidney involvement is present. For instance, in February 2024, Allecra Therapeutics, a Germany-based biopharmaceutical company, announced U.S. Food and Drug Administration (FDA) approval of EXBLIFEP (cefepime/enmetazobactam) for treating complicated urinary tract infections (cUTIs) in adults. The company also secured a five-year marketing exclusivity extension under the GAIN Act, which incentivizes the development of new anti-infective therapies. The study demonstrated that 79.1% of patients treated with cefepime/enmetazobactam achieved a composite response (clinical cure and microbiological eradication) compared to 58.9% of those treated with piperacillin/tazobactam.

What Are Latest Mergers And Acquisitions In The Complicated Urinary Tract Infection Treatment Market?

In June 2024, Orchid Pharma Limited, an India-based pharmaceutical company, partnered with Cipla Limited to introduce the antibiotic cefepime enmetazobactam in the Indian market. This collaboration aims to leverage Cipla’s distribution network to improve the accessibility of cefepime enmetazobactam, an antibiotic used to treat complicated urinary tract infection (UTI), including pyelonephritis. Cipla Limited is an India-based pharmaceutical company focused on developing and providing effective treatments for complicated urinary tract infections through advanced antibiotics and innovative healthcare solutions.

Regional Outlook

North America was the largest region in the complicated urinary tract infection treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Complicated Urinary Tract Infection Treatment Market?

The complicated urinary tract infection treatment market consists of sales of antibiotics, antifungals, and combination therapy. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Complicated Urinary Tract Infection Treatment Market Report 2026?

The complicated urinary tract infection treatment market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the complicated urinary tract infection treatment industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.